Articles

Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group

Univ. Grenoble Alpes. University Hospital, Grenoble France, Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309, UGA), Molecular biology department; Univ. Grenoble Alpes. University Hospital, Grenoble France, Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309, UGA), Oncohematology department
Univ. Grenoble Alpes. University Hospital, Grenoble France, Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309, UGA), Oncohematology department
Univ. Grenoble Alpes. University Hospital, Grenoble France, Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309, UGA), Research and innovation unit
Univ. Grenoble Alpes. University Hospital, Grenoble France, Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309, UGA), Research and innovation unit
Hematology Department Annecy hospital
Hematology Unit, Brest University Hospital, Brest France
Pathology Department, University Hospital, Nantes
Hematology Department, University Hospital, Montpellier
Hematology Department, Cancerology Institute Bergonie, Bordeaux
Hematology Department, University Hospital, Rennes
Hematology Department, University Hospital, Tours
Hematology Department, Dunkerque Hospital
Hematology Department, Chambery
Hematology Department, Bayonne Cote Basque Hospital
Hematology Department, University Hospital, Saint Etienne
Lymphoid malignancies Unit, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Créteil
IHBN – Hematology Department, University Hospital, Caen
Hematology Department, Cancerology Institute, Clermont-Ferrand
Hematology Department, Centre Henri Becquerel, Rouen
Institut Curie, Paris and Paris Saint Quentin University, UVSQ
Hematology Department, University Hospital, Caen
Hematology Department, University Hospital, Nancy
Hematology Department, University Hospital, Strasbourg
Hematology Department, University Hospital, Clermont-Ferrand
Hematology Department, University Hospital, Metz
Hematology Department, University Hospital, Bordeaux, Bordeaux
Hematology and cellular therapy Department, Hospital Saint Vincent de Paul, Université catholique de Lille
Hematology Department, Hospital Saint Quentin
Hematology Department, Hospital Chalon sur Saone
Hematology Department, Corbeil Hospital
Hematology department, Hospital La Roche Sur Yon
Hematology Department, University Hospital Angers
Hematology Department, Avignon Hospital
Hematology Department, University Hospital, Besançon
Hematology Department, Mulhouse Hospital
Hematology Department, Orleans Hospital
Onco-Hematology Department, University Hospital Poitiers and INSERM, CIC 1402, University of Poitiers
Hematology Department, Cancer Center Baclesse Caen
Institut universitaire du cancer de Toulouse Oncopole
Assistance Publique – Hôpitaux de Paris (APHP), Hôpital Cochin, Department of Pathology; Centre de Recherche des Cordeliers, Sorbonne University, Inserm, UMRS 1138, Université Paris Cité, F-75006 Paris
Unit For Innovation in Genetics and Epigenetics and Oncology. Dijon University Hospital
Institut Curie, Paris and Paris Saint Quentin University, UVSQ
Univ. Grenoble Alpes. University Hospital, Grenoble France, Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309, UGA), Oncohematology department
Haematologica Early view Nov 30, 2023 https://doi.org/10.3324/haematol.2023.283724